Day One Biopharma Files Proxy Statement for May Meeting
Ticker: DAWN · Form: DEF 14A · Filed: Apr 5, 2024 · CIK: 1845337
Sentiment: neutral
Topics: proxy-statement, annual-meeting, sec-filing
TL;DR
Day One Bio filed its proxy statement for the May 23rd meeting. Standard stuff, but check proposals for shareholder impact.
AI Summary
Day One Biopharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on April 5, 2024, for its annual meeting on May 23, 2024. The company, incorporated in Delaware and headquartered in Brisbane, CA, is in the pharmaceutical preparations industry. This filing is a standard procedural document for soliciting shareholder votes.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the upcoming annual meeting, including any proposals to be voted on, which can impact the company's governance and strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain new material financial information or strategic changes that would inherently increase risk.
Key Numbers
- 20240523 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20240405 — Filing Date (The proxy statement was officially filed with the SEC on this date.)
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- 2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005 (location) — Company Business and Mail Address
- May 23, 2024 (date) — Annual Meeting Date
- April 5, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting of stockholders scheduled for May 23, 2024.
When is the annual meeting of Day One Biopharmaceuticals, Inc. scheduled to take place?
The annual meeting is scheduled for May 23, 2024.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 5, 2024.
Where is Day One Biopharmaceuticals, Inc. headquartered?
Day One Biopharmaceuticals, Inc. is headquartered at 2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005.
What industry does Day One Biopharmaceuticals, Inc. operate in?
Day One Biopharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, as indicated by SIC code 2834.
Filing Stats: 4,630 words · 19 min read · ~15 pages · Grade level 12.5 · Accepted 2024-04-05 16:02:28
Filing Documents
- ny20017439x1_def14a.htm (DEF 14A) — 1071KB
- ny20017439x1_chart01.jpg (GRAPHIC) — 405KB
- ny20017439x1_chart02.jpg (GRAPHIC) — 724KB
- ny20017439x1_chart03.jpg (GRAPHIC) — 430KB
- ny20017439x1_chart04a.jpg (GRAPHIC) — 162KB
- ny20017439x1_chart04b.jpg (GRAPHIC) — 110KB
- ny20017439x1_chart05.jpg (GRAPHIC) — 442KB
- ny20017439x1_chart06.jpg (GRAPHIC) — 315KB
- ny20017439x1_check.jpg (GRAPHIC) — 8KB
- ny20017439x1_piechart01.jpg (GRAPHIC) — 173KB
- sig_jbender.jpg (GRAPHIC) — 18KB
- ny20017349x1_pc01.jpg (GRAPHIC) — 637KB
- ny20017349x1_pc02.jpg (GRAPHIC) — 623KB
- ny20017439x1_chart07x1.jpg (GRAPHIC) — 357KB
- ny20017439x1_pvp1x1.jpg (GRAPHIC) — 234KB
- ny20017439x1_pvp2x1.jpg (GRAPHIC) — 212KB
- 0001140361-24-018305.txt ( ) — 14453KB
- dawn-20240523.xsd (EX-101.SCH) — 5KB
- dawn-20240523_def.xml (EX-101.DEF) — 6KB
- dawn-20240523_lab.xml (EX-101.LAB) — 11KB
- dawn-20240523_pre.xml (EX-101.PRE) — 5KB
- ny20017439x1_def14a_htm.xml (XML) — 218KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 30 EXECUTIVE OFFICERS 32
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 33 REPORT OF THE COMPENSATION COMMITTEE 44 PAY VERSUS PERFORMANCE 50 EQUITY COMPENSATION PLAN INFORMATION 55 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 56 ADDITIONAL INFORMATION 57 OTHER MATTERS 59 TABLE OF CONTENTS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this proxy statement other than statements of historical fact, including statements regarding our future operating results and financial condition, our business strategy and plans, market growth, and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "aim," "may," "will," "should," "expect," "believe," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "seeks," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These statements are not historical facts and are based on current expectations, estimates, and projections about our industry, management's beliefs, and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates, and uncertainties that are difficult to predict. For a discussion of some of the risks and important factors that could affect our future results and financial condition, see "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other Securities and Exch